Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 71205-603

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 71205-603). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Image (Rabeprazole Dr Tablet 01)

Chemical structure of rabeprazole sodium, the active ingredient in RABEPRAZOLE SODIUM 20 mg delayed-release oral tablets by Proficient Rx LP.*

FDA Label Image

Figure 2: Mean Daytime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 02)

A line graph showing mean heartburn scores over a 28-day study period for three groups: placebo, rabeprazole 10 mg, and rabeprazole 20 mg. Scores are measured from 0 (none) to 4 (very severe). The graph indicates a decrease in heartburn scores post-study start (day 0) for all groups, with differences among treatment groups visible over time.*

FDA Label Image

Figure 3: Mean Nighttime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 03)

A line graph depicting mean heartburn scores over a 28-day study period for three groups: placebo, rabeprazole 10 mg, and rabeprazole 20 mg. The x-axis represents study days, including pre-study days, and the y-axis shows mean heartburn scores from 0 (none) to 4 (very severe). The graph shows decreasing heartburn scores for both rabeprazole groups compared to placebo after day 0.*

FDA Label Image

Figure 4: Mean Daytime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 04)

A line graph comparing mean heartburn scores over time between placebo and RAB 20mg treatment groups. The X-axis represents study days from -14 to 28, with a vertical line at day 0. The Y-axis shows mean heartburn scores from 0 (none) to 4 (very severe). Two trend lines illustrate changes in scores for placebo (dashed line) and RAB 20mg (solid line) groups across the study period.*

FDA Label Image

Figure 5: Mean Nighttime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 05)

A line graph comparing mean heartburn scores over a 28-day study period between a placebo group (n=58) and a group treated with 20 mg rabeprazole sodium (n=59). The x-axis represents study days from -14 to 28, with 0 indicating the start of treatment, and the y-axis shows mean heartburn scores from 0 (none) to 4 (very severe). The graph demonstrates the changes in heartburn severity during the study.*

FDA Label Image

71205-603-30 (Rabeprazole Dr Tablet 30s Label)

Label for Rabeprazole Sodium 20 mg delayed-release tablets by Proficient Rx LP. The label indicates 60 tablets per container with each tablet containing 20 mg rabeprazole sodium. The tablets are described as light yellow, round, biconvex with beveled edges, printed with "B683" on one side. The label includes the NDC 71205-603-60 and manufacturing details from Rubicon Research Private Limited, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.